Tamoxifen (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

目錄號: HY-13757A 純度: 99.78%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南

摩爾計(jì)算器

Tamoxifen (ICI 47699) 是一種口服有效的，選擇性雌激素受體 (estrogen receptor) 調(diào)節(jié)劑 (SERM)，可阻斷乳腺細(xì)胞中的雌激素作用，并可激活其他細(xì)胞，如骨骼，肝臟和子宮細(xì)胞中的雌激素活性。Tamoxifen 是一種有效的 Hsp90 激活劑，可增強(qiáng) Hsp90 分子伴侶 ATPase 的活性。Tamoxifen 還可以有效抑制傳染性 EBOV Zaire 和 Marburg (MARV)，IC₅₀ 分別為 0.1 μM 和 1.8 μM。Tamoxifen 可以激活自噬 (autophagy)，誘導(dǎo)凋亡 (apoptosis)。Tamoxifen 還可以誘導(dǎo) CreER(T2) 轉(zhuǎn)基因小鼠的基因敲除。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個人用途提供產(chǎn)品和服務(wù)

Tamoxifen Chemical Structure

CAS No. : 10540-29-1

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥550	In-stock
100 mg	￥190	In-stock
200 mg	￥300	In-stock
500 mg	￥500	In-stock
1 g	￥690	In-stock
5 g	￥2750	In-stock
10 g	￥3500	In-stock
50 g		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Tamoxifen:

Tamoxifen-d₅ In-stock
Tamoxifen Citrate In-stock
Tamoxifen (Standard) In-stock
Tamoxifen-d₃ 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 114 篇科研文獻(xiàn)

•Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7. [Abstract]
•Cell. 2024 Sep 5;187(18):5064-5080.e14. [Abstract]
•Immunity. 2023 Dec 22:S1074-7613(23)00534-4. [Abstract]
•Glia. 2023 Nov 1. [Abstract]
•Signal Transduct Target Ther. 2023 Feb 3;8(1):51. [Abstract]
•Cell. 2022 Aug 4;185(16):3008-3024.e16. [Abstract]

•Immunity. 2022 Jul 12;S1074-7613(22)00291-6. [Abstract]
•Immunity. 2020 Nov 17;53(5):1078-1094.e7. [Abstract]
•Cell Mol Immunol. 2024 Jul 19. [Abstract]
•Gut. 2022 May 25;gutjnl-2022-327166. [Abstract]
•Cancer Commun (Lond). 2024 Sep 28. [Abstract]
•Brain Behav Immun. 2023 Nov 20.
•Nat Commun. 2024 Sep 6;15(1):7791. [Abstract]
•Bone Res. 2024 Sep 6;12(1):53. [Abstract]
•Theranostics. 2024 Aug 1;14(11):4499-4518. [Abstract]
•Sci Adv. 2024 Jul 19;10(29):eadp5239. [Abstract]
•Cancer Res. 2024 Aug 13. [Abstract]
•J Adv Res. 2024 Aug 3:S2090-1232(24)00323-0. [Abstract]
•Sci Adv. 2024 Jul 5;10(27):eadm7373. [Abstract]
•Adv Sci (Weinh). 2024 Jun 5:e2401676. [Abstract]
•Dev Cell. 2024 May 25:S1534-5807(24)00324-1. [Abstract]
•J Exp Clin Cancer Res. 2024 Jun 20;43(1):173. [Abstract]
•Cardiovasc Res. 2024 Jun 4:cvae116. [Abstract]
•Sci Adv. 2024 Feb 2;10(5):eadj7813. [Abstract]
•Sci Adv. 2023 Sep;9(35):eadg7125. [Abstract]
•J Hazard Mater. 2023 Sep 7;460:132489. [Abstract]
•Redox Biol. 18 October 2022, 102509.
•Nucleic Acids Res. 2022 Sep 17;gkac778. [Abstract]
•J Adv Res. 11 January 2022.
•Theranostics. 2021 Sep 21;11(19):9623-9651. [Abstract]
•Theranostics. 2020 Sep 11;10(24):11159-11177. [Abstract]
•Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
•Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]
•J Neuroinflammation. 2024 Nov 14;21(1):295. [Abstract]
•Cell Prolif. 2024 Jun 26:e13700. [Abstract]
•Cell Rep. 2024 May 10;43(5):114226. [Abstract]
•Cancer Lett. 2024 Apr 1:590:216839. [Abstract]
•Cell Rep. 2024 Feb 15;43(2):113786. [Abstract]
•Cell Rep. 2024 Feb 17;43(2):113804. [Abstract]
•Cancer Lett. 2024 Jan 9:216609. [Abstract]
•Cell Death Dis. 2023 Dec 5;14(12):796. [Abstract]
•Cell Rep. 2023 Sep 30;42(10):113202. [Abstract]
•Cell Rep. 2023 Sep 19;42(10):113158. [Abstract]
•Cell Prolif. 2023 Jan 24;e13406. [Abstract]
•Proc Natl Acad Sci U S A. 2023 Jan 3;120(1):e2203779120. [Abstract]
•Proc Natl Acad Sci U S A. 2022 Oct 4;119(40):e2204716119. [Abstract]
•Br J Cancer. 2022 May 26. [Abstract]
•Cell Death Dis. 2021 Oct 26;12(11):1003. [Abstract]
•Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):e2024258118. [Abstract]
•Cell Prolif. 2021 Jan;54(1):e12953. [Abstract]
•Chemosphere. 2020 Jan;239:124705. [Abstract]
•Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]
•Br J Pharmacol. 2024 Jun 16. [Abstract]
•Breast Cancer Res. 2024 Mar 11;26(1):44. [Abstract]
•Phytomedicine. 2024 Feb 22, 155461.
•Cell Mol Life Sci. 2024 Jan 22;81(1):49. [Abstract]
•J Invest Dermatol. 2023 Jun 30;S0022-202X(23)02399-0. [Abstract]
•Cell Mol Life Sci. 2023 Mar 18;80(4):100. [Abstract]
•Transl Res. 2023 Feb 6;S1931-5244(23)00018-X. [Abstract]
•J Med Chem. 2020 Oct 8;63(19):11085-11099. [Abstract]
•Biomacromolecules. 2015 Sep 14;16(9):2701-14. [Abstract]
•Mol Cell Biochem. 2024 Sep 9. [Abstract]
•J Steroid Biochem Mol Biol. 2024 Aug 13:106599. [Abstract]
•J Neurosci. 2024 Jun 19:e2192232024. [Abstract]
•Biochem Pharmacol. 2024 May 9:225:116256. [Abstract]
•Viruses. 2024 Apr 20;16(4):643. [Abstract]
•Front Immunol. 2024 Mar 13.
•Cell Signal. 2024 Feb 4:117:111080. [Abstract]
•Chem Biol Interact. 2024 Jan 6:110865. [Abstract]
•J Cell Mol Med. 2023 Oct 27. [Abstract]
•J Ethnopharmacol. 2023 Aug 23;117075. [Abstract]
•Cancers (Basel). 2023 Aug 11, 15(16), 4066.
•Mbio. 2023 Apr 3;e0054923. [Abstract]
•Chem Biol Interact. 2022 Aug 6;110091. [Abstract]
•Front Immunol. 2022 Mar 10;13:805420. [Abstract]
•NPJ Breast Cancer. 2022 Mar 10;8(1):31. [Abstract]
•Int J Mol Sci. 2022, 23(5), 2664.
•Pharmaceutics. 2022, 14(1), 176.
•Biochem Pharmacol. 2021 Jun;188:114583. [Abstract]
•J Clin Endocrinol Metab. 2021 Feb 1;dgab020. [Abstract]
•Cancers. 2021 Feb 3;13(4):599. [Abstract]
•RNA Biol. 2020 Sep 20;1-13. [Abstract]
•J Cell Mol Med. 2020 Jan;24(2):1599-1613. [Abstract]
•Heliyon. 2024 June 15.
•Int J Biochem Cell Biol. 2024 May 9:172:106585. [Abstract]
•J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Mar 26:1237:124100. [Abstract]
•Breast Cancer Res Treat. 2023 Sep 11. [Abstract]
•Biochim Biophys Acta Gen Subj. 2023 Jun 16;130413. [Abstract]
•Bioorg Med Chem. 2023 Mar 7;82:117235. [Abstract]
•Front Genet. 2022 Sep 20;13:992444. [Abstract]
•Cardiovasc Drugs Ther. 2022 Nov 9. [Abstract]
•Toxicol Res (Camb). 22 July 2022.
•J Pharmaceut Biomed. 2020, 113870.
•Biochem Biophys Res Commun. 2020 Feb 19;522(4):862-868. [Abstract]
•Am J Transl Res. 2018 Jul 15;10(7):2184-2194. [Abstract]
•Patent. US20240217988A1.
•bioRxiv. 2024 August 04.
•Res Sq. 2024 Jun 04.
•bioRxiv. 2024 Apr 28.
•SSRN. 2024 Mar 26.
•SSRN. 2024 Jan 10.
•Journal of the Institute of Science and Technology. 2023 Mar 3, 13(4), 2997-3006.
•bioRxiv. 2023 Dec 18.
•Research Square Preprint. 2023 Aug 7.
•bioRxiv. 2023 Aug 22.
•bioRxiv. 2023 Jun 22.
•bioRxiv. 2023 Mar 15.
•bioRxiv. 2023 Feb 7.
•bioRxiv. 2023 Jan 31.
•Universität Basel. Philosophisch-Naturwissenschaftlichen Fakultät.
•Research Square Preprint. 2022 May.
•Research Square Preprint. 2021 Oct.
•Research Square Preprint. 2020 Nov 4;rs.3.rs-100914. [Abstract]
•bioRxiv. 2020 Mar.

: Tamoxifen purchased from MCE. Usage Cited in: Redox Biol. 18 October 2022, 102509.; Expression of TFRC in primary fibroblasts from TFRCflox/flox and TFRC?/? mice was assessed by western blot after 5 days of Tamoxifen intraperitoneal injection and 7 days of waiting.

: Tamoxifen purchased from MCE. Usage Cited in: Clin Transl Med. 2020 Jan;10(1):137-150. [Abstract]; Different transmission of MAPK8/FoxO signaling pathway in breast cancer cells (MCF-7, T47D, ZR-75, and MDA-MB-231) and liver cells (LO2) exposed to TAM (Tamoxifen).

: Tamoxifen purchased from MCE. Usage Cited in: Cell Commun Signal. 2019 May 23;17(1):50. [Abstract]; Tamoxifen inhibits the growth and metastasis of prostate tumors in vivo. Western blot analysis of the indicated proteins in prostate primary tumors tissues.

Tamoxifen 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

查看所有亞型

Estrogen receptor ERα ERβ ERRα ERRβ ERRγ

查看 HSP 亞型特異性產(chǎn)品:

查看所有亞型

HSP40 HSP70 HSP90 HSP105 HSF1 HSP HSPA5

生物活性
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells^[1]^[2]^[3]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively^[5]. Tamoxifen activates autophagy and induces apoptosis^[4]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse^[6].

IC₅₀ & Target^[1]^[4]

Estrogen receptor

HSP90

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
518A2	IC₅₀	7.62 μM Compound: 2	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2058	EC₅₀	12.5 μM Compound: TAM	Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay Antiproliferative activity against human A2058 cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay	[PMID: 31099568]
A253 cell line	IC₅₀	8.92 μM Compound: 2	Cytotoxicity against human A253 cells after 96 hrs by SRB assay Cytotoxicity against human A253 cells after 96 hrs by SRB assay	[PMID: 22749392]
A2780	GI₅₀	30.3 μM Compound: 1	Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human A2780 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 27128175]
A2780	IC₅₀	7.77 μM Compound: 2	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 22749392]
A-431	IC₅₀	> 100 μM Compound: Tamoxifen	Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human A549 cells by alamar blue assay Cytotoxicity against human A549 cells by alamar blue assay	[PMID: 11720540]
A549	IC₅₀	10.08 μM Compound: Tamoxifen	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
A549	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human A549 cells by MTT assay Antiproliferative activity against human A549 cells by MTT assay	[PMID: 31546197]
A549	IC₅₀	12 μM Compound: TAM	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 23287057]
A549	IC₅₀	17.3 μM Compound: Tamoxifen	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
A549	IC₅₀	17.3 μM Compound: Tamoxifen	Anticancer activity against human A549 cells measured after 48 hrs by SRB assay Anticancer activity against human A549 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
A549	GI₅₀	24.4 μM Compound: Tamoxifen	Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human A549 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
A549	IC₅₀	8.4 μM Compound: Tamoxifen	Cytotoxicity against human A549 cells assessed as cell viability by MTT assay Cytotoxicity against human A549 cells assessed as cell viability by MTT assay	[PMID: 26079090]
A549	IC₅₀	9.66 μM Compound: 2	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 22749392]
Astrocyte	IC₅₀	> 10 μM Compound: Tamoxifen	Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method Cytotoxicity against normal human astrocytes assessed as cell viability incubated for 72 hrs by WST-1 method	[PMID: 26355532]
B16-F10	IC₅₀	64.87 μM Compound: Tam	Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay	[PMID: 25222876]
CHO	IC₅₀	> 100 μM Compound: Tam	Antiproliferative activity against CHO cells after 2 days by MTT assay Antiproliferative activity against CHO cells after 2 days by MTT assay	[PMID: 25222876]
DLD-1	IC₅₀	11.06 μM Compound: Tamoxifen	Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay Anticancer activity against human DLD1 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
DLD-1	IC₅₀	16.3 μM Compound: Tamoxifen	Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
DLD-1	IC₅₀	4.78 μM Compound: 2	Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay	[PMID: 22749392]
DU-145	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human DU145 cells by MTT assay Antiproliferative activity against human DU145 cells by MTT assay	[PMID: 31546197]
DU-145	IC₅₀	18.07 μM Compound: Tamoxifen	Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay Anticancer activity against human DU145 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
DU-145	GI₅₀	19.3 μM Compound: Tamoxifen	Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human DU145 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
DU-145	IC₅₀	28.9 μM Compound: Tamoxifen	Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
DU-145	IC₅₀	5.5 μM Compound: TAM	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	[PMID: 23287057]
DU-145	GI₅₀	6.07 μM Compound: Tamoxifen	Anticancer activity against human DU145 cells after 24 hrs by SRB assay Anticancer activity against human DU145 cells after 24 hrs by SRB assay	[PMID: 19733085]
EKVX	GI₅₀	6.3 μM Compound: TAM	Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human EKVX cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
FaDu	IC₅₀	5.39 μM Compound: Tamoxifen	Anticancer activity against human FADU cells measured after 48 hrs by SRB assay Anticancer activity against human FADU cells measured after 48 hrs by SRB assay	[PMID: 27671497]
Fibroblast	IC₅₀	> 20 μM Compound: TAM	Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay Antiproliferative activity against mouse fibroblasts after 48 hrs by MTT assay	[PMID: 23287057]
Fibroblast	CC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HSF cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
Fibroblast	CC₅₀	12.7 μM Compound: Tamoxifen	Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against human HSF cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
HCT-116	IC₅₀	45 μM Compound: Tamoxifen	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
HCT-15	GI₅₀	3.16 μM Compound: TAM	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human HCT15 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
HEK293	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells by MTT assay Cytotoxicity against HEK293 cells by MTT assay	[PMID: 31546197]
HEK293	IC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells after 24 hrs by MTT assay Cytotoxicity against HEK293 cells after 24 hrs by MTT assay	[PMID: 20605470]
HEK293	IC₅₀	10 μM Compound: Tamoxifen	Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against human HEK293 cells after 48 hrs by MTT assay	[PMID: 21871812]
HEK293	CC₅₀	13 μg/mL Compound: TAM	Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30316060]
HEK293	CC₅₀	13.1 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay Cytotoxicity against HEK293 cells assessed as decrease in cell viability after 20 hrs by resazurin dye-based fluorescence assay	[PMID: 30901686]
HEK293	CC₅₀	13.1 μg/mL Compound: Tamoxifen	Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay Cytotoxicity against human HEK293 cells assessed as reduction in cell growth incubated for 20 hrs by resazurin dye-based fluorometric assay	[PMID: 30831407]
HEK293	IC₅₀	20.93 μM Compound: Tamoxifen	Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay Antiproliferative activity against HEK293 cells after 48 hrs by MTT assay	[PMID: 29054359]
HEK293	IC₅₀	22.4 μM Compound: TAM	Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
HEK293	IC₅₀	24 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay Cytotoxicity against HEK293 cells assessed as cell growth inhibition measured after 20 hrs by resazurin dye based assay	[PMID: 35477062]
HEK293	IC₅₀	24 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay	[PMID: 30975502]
HEK293	IC₅₀	26 μM Compound: TAM	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 24457094]
HEK293	IC₅₀	26.33 μM Compound: 1	Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
HEK293	CC₅₀	39.4 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against HEK293 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30322754]
HEK293	IC₅₀	50 μM Compound: Tamoxifen	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	[PMID: 24880230]
HEK293	CC₅₀	62 μM Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay Cytotoxicity against HEK293 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay	[PMID: 28257200]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay Cytotoxicity against HEK293 cells assessed as cell viability after 20 hrs by fluorescence assay	[PMID: 33609657]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay Cytotoxicity against HEK293 cells measured after 20 hrs by resazurin dye based fluorescence assay	[PMID: 32619924]
HEK293	CC₅₀	9 μg/mL Compound: Tamoxifen	Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method Cytotoxicity against human HEK-293 cells incubated for 23 hrs by CO-ADD method	[PMID: 33738069]
HEK-293T	IC₅₀	0.039 μM Compound: Tamoxifen	Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay Antagonist activity at Gal4 DBD-fused human ERalpha LBD expressed in HEK293T cells assessed as inhibition of estradiol-induced transcriptional activation after 20 hrs by luciferase reporter gene assay	[PMID: 23786452]
HeLa	IC₅₀	0.341 μM Compound: Tamoxifen	Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay Antagonist activity at full length ERalpha (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay	[PMID: 28882502]
HeLa	IC₅₀	0.73 μM Compound: Tamoxifen	Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay	[PMID: 29624387]
HeLa	IC₅₀	1.53 μM Compound: Tamoxifen	Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay Antagonist activity at full length ERbeta (unknown origin) expressed in human HeLa cells incubated for 24 hrs by ERE-driven luciferase reporter gene assay	[PMID: 28882502]
HeLa	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human HeLa cells by MTT assay Antiproliferative activity against human HeLa cells by MTT assay	[PMID: 31546197]
HeLa	GI₅₀	12 μM Compound: 1	Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay Cytotoxicity against human HeLa cells assessed as cell growth inhibition after 72 hrs by trypan blue assay	[PMID: 27128175]
HeLa	IC₅₀	12.5 μM Compound: Tamoxifen	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	[PMID: 20605470]
HeLa	GI₅₀	32.6 μM Compound: 1	Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay Antiproliferative activity against human HeLa cells after 72 hrs by trypan blue assay	[PMID: 23735829]
HeLa	IC₅₀	8.85 μM Compound: Tamoxifen	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay	[PMID: 28838694]
Hepatocyte	EC₅₀	34.4 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay	[PMID: 22531045]
Hepatocyte	EC₅₀	67.6 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay	[PMID: 22531045]
Hepatocyte	EC₅₀	71.4 μM Compound: Tamoxifen	Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay	[PMID: 22531045]
HepG2	IC₅₀	12 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 30613327]
HepG2	IC₅₀	19.6 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by cell-titer 96 aqueous one solution cell proliferation assay	[PMID: 34015704]
HepG2	GI₅₀	21.7 μM Compound: Tamoxifen	Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human HepG2 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
HepG2	IC₅₀	23.4 μM Compound: tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
HepG2	CC₅₀	24.7 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis Cytotoxicity against human HepG2 cells after 24 hrs by resazurin dye-based fluorescence analysis	[PMID: 30322754]
HepG2	EC₅₀	35 μM Compound: Tamoxifen	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 4 hrs by CellTiter-Glo assay	[PMID: 27652492]
HepG2	EC₅₀	35 μM Compound: Tamoxifen	Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay Cytotoxicity in human HepG2 cells assessed as induction of cell necrosis incubated for 4 hrs by LDH release assay	[PMID: 27652492]
HepG2	IC₅₀	6.3 μM Compound: TAM	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23287057]
HepG2	CC₅₀	62 μM Compound: Tamoxifen	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin based assay	[PMID: 28257200]
HL-60	IC₅₀	14.3 μM Compound: Tamoxifen	Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS Cytotoxicity against human HL60 cells after 72 hrs by WST1 assay in presence of 20% FBS	[PMID: 22901895]
HL-60	IC₅₀	5.9 μg/mL Compound: 1, Tamoxifen	Growth inhibition of human HL60 cells after 4 hrs by MTT assay Growth inhibition of human HL60 cells after 4 hrs by MTT assay	[PMID: 17904372]
HT-29	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human HT-29 cells by alamar blue assay Cytotoxicity against human HT-29 cells by alamar blue assay	[PMID: 11720540]
HT-29	IC₅₀	38.6 μM Compound: tamoxifen	Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay Cytotoxicity against human HT-29 cells after 24 hrs by CellTiter-BlueCell viability assay	[PMID: 20545334]
Ishikawa	IC₅₀	0.42 μM Compound: tamoxifen	Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 4 days by ELISA	[PMID: 9784163]
Ishikawa	IC₅₀	14.58 μM Compound: Tamoxifen	Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against ER-positive human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34509864]
Ishikawa	IC₅₀	16.47 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 28460819]
Ishikawa	IC₅₀	16.78 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human Ishikawa cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34022716]
Ishikawa	IC₅₀	170 nM Compound: 1a	Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs Antiestrogenic activity in human Ishikawa cells assessed as inhibition of estrogen-induced alkaline phosphatase activity after 72 hrs	[PMID: 18835176]
Ishikawa	IC₅₀	20.65 μM Compound: Tamoxifen	Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity in human Ishikawa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 28942113]
Ishikawa	IC₅₀	22.5 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
Ishikawa	IC₅₀	26.52 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells after 48 hrs by MTT assay	[PMID: 29587221]
Ishikawa	IC₅₀	6 μM Compound: Tamoxifen	Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay Antiproliferative activity against human Ishikawa cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
Ishikawa	IC₅₀	7.87 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human Ishikawa cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
J774.A1	CC₅₀	11.06 μM Compound: Tamoxifen	Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability incubated for 24 hrs by neutral red uptake assay	[PMID: 31376569]
Jurkat	IC₅₀	8.3 μM Compound: Tamoxifen	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 23792352]
K562	GI₅₀	5.2 μM Compound: tamoxifen	Antiproliferative activity against human K562 cells after 72 hrs Antiproliferative activity against human K562 cells after 72 hrs	[PMID: 25420175]
MCF-10A	IC₅₀	> 1000 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 24 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	> 1000 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Cytotoxicity against human MCF-10A cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF-10A	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay Cytotoxicity against human MCF-10A cells after 48 hrs by MTT assay	[PMID: 33340662]
MCF7	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MCF7	EC₅₀	> 200 nM Compound: 2	Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay Antiproliferative activity against human MCF-7 cells incubated for 72 hrs by Cell-titer Glo assay	[PMID: 34251202]
MCF7	IC₅₀	0.027 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 22472045]
MCF7	IC₅₀	0.794 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 5 days Cytotoxicity against human MCF7 cells after 5 days	[PMID: 23864928]
MCF7	IC₅₀	1 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 20451380]
MCF7	IC₅₀	1.31 μg/mL Compound: Tamoxifen	Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of colony formation measured after 3 weeks by crystal violet staining based soft agar colony formation assay	[PMID: 31884407]
MCF7	GI₅₀	1.58 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MCF7	IC₅₀	1.82 μM Compound: TAMOX, TAM	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 23123017]
MCF7	IC₅₀	1.89 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 24721727]
MCF7	EC₅₀	10 nM Compound: 3 (Tamoxifen)	Effective concentration against MCF-7 breast tumor cells using MCF-7 assay. Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.	[PMID: 12825935]
MCF7	IC₅₀	10 μM Compound: tamoxifene	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 19423356]
MCF7	IC₅₀	10.74 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MCF7 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MCF7	IC₅₀	10.87 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT assay Antiproliferative activity against human MCF7 cells by MTT assay	[PMID: 31546197]
MCF7	IC₅₀	10.9 μM Compound: Tamoxifen	Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay Cytotoxicity against human adriamycin- resistant MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11 μM Compound: Tamoxifen	Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay	[PMID: 12565971]
MCF7	IC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay Cytotoxicity against human tamoxifen-resistant MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11.35 μM Compound: Tamoxifen	Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against ER positive human MCF7 cells after 48 hrs by MTT assay	[PMID: 28460819]
MCF7	IC₅₀	11.4 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by WST-1 assay Cytotoxicity against human MCF7 cells by WST-1 assay	[PMID: 19836230]
MCF7	IC₅₀	11.44 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23022281]
MCF7	IC₅₀	11.55 μM Compound: Tamoxifen	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MCF7	IC₅₀	11.8 μM Compound: Tamoxifen	Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay Anticancer activity against human MCF7 cells expressing estrogen receptor by MTT assay	[PMID: 20951035]
MCF7	IC₅₀	12 μM Compound: tamoxifen	Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay Anticancer activity against estrogen-positive human MCF7 cells after 18 hrs by MTT assay	[PMID: 19446930]
MCF7	GI₅₀	12 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay Antiproliferative activity against human MCF7 cells after 72 hrs by trypan blue assay	[PMID: 23735829]
MCF7	IC₅₀	12.35 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23830503]
MCF7	IC₅₀	12.48 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
MCF7	IC₅₀	12.5 μM Compound: Tam	Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ER after 48 hrs by MTT assay	10.1039/C4MD00289J
MCF7	IC₅₀	13.45 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23902804]
MCF7	IC₅₀	13.7 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by MTT reduction assay Antiproliferative activity against human MCF7 cells by MTT reduction assay	[PMID: 33421712]
MCF7	IC₅₀	14.35 μM Compound: Tamoxifen	Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 28942113]
MCF7	IC₅₀	15.2 μM Compound: 6	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23880359]
MCF7	IC₅₀	15.21 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 33340662]
MCF7	IC₅₀	15.46 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29587221]
MCF7	IC₅₀	15.6 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells expressing ERalpha and ERbeta assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MCF7	IC₅₀	16.7 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30384047]
MCF7	IC₅₀	18.18 μM Compound: Tamoxifen	Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay Anticancer activity against human ER-positive MCF7 cells measured after 48 hrs by SRB assay	[PMID: 27671497]
MCF7	IC₅₀	18.71 μM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated at 37 degC for 3 days by resazurin microplate assay	[PMID: 25734623]
MCF7	IC₅₀	19.2 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin based fluorescence assay	[PMID: 33852304]
MCF7	IC₅₀	19.33 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by resazurin microplate assay	[PMID: 27311894]
MCF7	IC₅₀	19.5 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29482944]
MCF7	IC₅₀	19.54 μM Compound: Tam	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 24 hrs by MTT assay	[PMID: 22647217]
MCF7	IC₅₀	2.1 μM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay Antiproliferative activity against human MCF7 cells after 5 days by WST-8 assay	[PMID: 25614118]
MCF7	IC₅₀	20 nM Compound: 7	Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
MCF7	IC₅₀	200 nM Compound: Tamoxifen	Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method Antagonist activity at ERalpha receptor in human MCF7 cells assessed as inhibition of cell growth after 6 days by crystal violet staining method	[PMID: 23448346]
MCF7	IC₅₀	21.57 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay	[PMID: 28505536]
MCF7	IC₅₀	22.6 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31620225]
MCF7	IC₅₀	25 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay Antiproliferative activity against human MCF7cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay	[PMID: 31673312]
MCF7	IC₅₀	25 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method Antiproliferative activity against human MCF7 cells by fluorescence based viable cell counting method	[PMID: 31610378]
MCF7	IC₅₀	27.96 μM Compound: 1, TAM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 23860592]
MCF7	IC₅₀	3.8 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay Cytotoxicity against human MCF7 cells assessed as cell viability by MTT assay	[PMID: 26079090]
MCF7	IC₅₀	3.99 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MCF7 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MCF7	IC₅₀	30 nM Compound: Tam	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 6 days by SRB assay	[PMID: 33257172]
MCF7	IC₅₀	31 μM Compound: TEM	Cytotoxicity activity against human MCF7 cells by MTS assay Cytotoxicity activity against human MCF7 cells by MTS assay	[PMID: 21680064]
MCF7	IC₅₀	4 μM Compound: TAM	Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay Cytotoxicity against human MCF7 Cells after 48 hrs by neutral red dye-based assay	[PMID: 31129455]
MCF7	IC₅₀	4.1 μM Compound: 2a	Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against ER-dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 28426931]
MCF7	IC₅₀	4.1 μM Compound: 2	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 25369367]
MCF7	IC₅₀	4.1 μM Compound: Tamoxifen	Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay Antiproliferative activity against ER-positive human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by AlamarBlue assay	[PMID: 27407030]
MCF7	IC₅₀	4.12 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	[PMID: 31987694]
MCF7	IC₅₀	4.12 μM Compound: 1a	Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against estrogen receptor dependent human MCF7 cells after 72 hrs by MTT assay	[PMID: 18835176]
MCF7	IC₅₀	4.4 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 26896706]
MCF7	IC₅₀	4.4 μM Compound: 2a	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by SRB assay	[PMID: 28426931]
MCF7	IC₅₀	4.67 μM Compound: Tam	Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay	[PMID: 25222876]
MCF7	IC₅₀	42.4 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30731397]
MCF7	ED₅₀	5 μg/mL Compound: TAM	Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells expressing estrogen receptor after 72 hrs by SRB assay	[PMID: 19425534]
MCF7	IC₅₀	5.09 μM Compound: TAM	Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs Antiproliferative activity against MCF7 cells at 3 mg/kg/day after 48 hrs	[PMID: 16979337]
MCF7	IC₅₀	5.19 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 23806014]
MCF7	IC₅₀	5.3 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
MCF7	IC₅₀	5.3 μM Compound: Tamoxifen	Growth inhibition of human MCF7 cells after 72 hrs by MTT assay Growth inhibition of human MCF7 cells after 72 hrs by MTT assay	[PMID: 29220789]
MCF7	IC₅₀	5.4 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 34726897]
MCF7	IC₅₀	5.5 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 23287057]
MCF7	IC₅₀	5.62 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33894490]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay	[PMID: 36846377]
MCF7	IC₅₀	50 μM Compound: Tamoxifen	Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human ER-positive MCF7 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26972118]
MCF7	IC₅₀	54 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 33234343]
MCF7	IC₅₀	55.5 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MCF7 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
MCF7	IC₅₀	580 nM Compound: tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTS assay	[PMID: 18272256]
MCF7	IC₅₀	580 nM Compound: 3 (Tamoxifen)	Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay. Inhibitory concentration against MCF-7 breast tumor cells using MCF-7 assay.	[PMID: 12825935]
MCF7	IC₅₀	6 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24880230]
MCF7	IC₅₀	6.3 μM Compound: Tamoxifen	Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
MCF7	GI₅₀	6.5 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by trypan blue assay	[PMID: 27128175]
MCF7	GI₅₀	6.8 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
MCF7	IC₅₀	6.99 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by resazurin microplate assay Cytotoxicity against human MCF7 cells by resazurin microplate assay	[PMID: 27228159]
MCF7	IC₅₀	64.3 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 25164760]
MCF7	IC₅₀	7.09 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 30360952]
MCF7	IC₅₀	7.1 μM Compound: 2	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 22749392]
MCF7	IC₅₀	7.65 μM Compound: TAM	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 19740667]
MCF7	IC₅₀	7.94 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay Cytotoxicity against human MCF7 cells after 72 hrs by resazurin based fluorescence assay	[PMID: 28927795]
MCF7	IC₅₀	8 μg/mL Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 48 hrs by sulforhodamine B assay	[PMID: 24576797]
MCF7	GI₅₀	8 μM Compound: Tamoxifen	Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay Anti-proliferative activity against human MCF7 cells incubated for 48 hrs by SRB assay	[PMID: 26163220]
MCF7	IC₅₀	8.12 μM Compound: Tamoxifen	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 29054359]
MCF7	IC₅₀	8.31 μg/mL Compound: TAM	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 21115211]
MCF7	IC₅₀	8.38 μg/mL Compound: Tamoxifen	Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay Anticancer activity against human MCF7 cells assessed a cell growth inhibition incubated for 48 hrs by SRB assay	[PMID: 32771798]
MCF7	IC₅₀	8.42 μM Compound: TAM	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MCF7	IC₅₀	8.5 μg/mL Compound: Tamoxifen	Cytotoxicity against human MCF7 cells by SRB assay Cytotoxicity against human MCF7 cells by SRB assay	[PMID: 36325400]
MCF7	IC₅₀	8.53 μM Compound: 1	Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
MCF7	IC₅₀	8.6 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS Cytotoxicity against human MCF7 cells after 72 hrs by WST1 assay in presence of 20% FBS	[PMID: 22901895]
MCF7	IC₅₀	8.61 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	[PMID: 29605808]
MCF7	IC₅₀	8.9 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20605470]
MCF7	IC₅₀	82.5 μM Compound: Tamoxifen	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25164760]
MCF7	IC₅₀	9 μM Compound: Tamoxifen	Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay	[PMID: 32731188]
MCF7	IC₅₀	9 μM Compound: TAM	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 24457094]
MCF7	IC₅₀	9.6 μM Compound: Tamoxifen	Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ER and PR-positive human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
MDA-MB-231	IC₅₀	> 20 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
MDA-MB-231	IC₅₀	> 50 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 48 hrs by CCK8 assay	[PMID: 34022716]
MDA-MB-231	IC₅₀	> 50 μM Compound: Tamoxifen	Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay Cytotoxicity against human ER-negative MDA-MB-231 cells assessed as cell viability after 72 hrs by MTT assay	[PMID: 26972118]
MDA-MB-231	IC₅₀	0.66 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 20451380]
MDA-MB-231	IC₅₀	10 μM Compound: TAM	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24457094]
MDA-MB-231	IC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 20605470]
MDA-MB-231	IC₅₀	10.11 μM Compound: TAM	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
MDA-MB-231	IC₅₀	11.2 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT assay Antiproliferative activity against human MDA-MB-231 cells by MTT assay	[PMID: 31546197]
MDA-MB-231	IC₅₀	11.4 μM Compound: TAM	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23287057]
MDA-MB-231	IC₅₀	12.4 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells by WST-1 assay Cytotoxicity against human MDA-MB-231 cells by WST-1 assay	[PMID: 19836230]
MDA-MB-231	IC₅₀	12.41 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 23022281]
MDA-MB-231	IC₅₀	13.9 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	[PMID: 27176944]
MDA-MB-231	IC₅₀	14 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 24880230]
MDA-MB-231	IC₅₀	14.5 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay Antiproliferative activity against human MDA-MB-231 cells by MTT reduction assay	[PMID: 33421712]
MDA-MB-231	IC₅₀	14.94 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs by MTT assay	[PMID: 35276362]
MDA-MB-231	IC₅₀	15.01 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 72 hrs by MTT assay	[PMID: 33894490]
MDA-MB-231	GI₅₀	15.1 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
MDA-MB-231	IC₅₀	17 μM Compound: Tamoxifen	Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against ERalpha and ERbeta-deficient human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
MDA-MB-231	IC₅₀	18.48 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
MDA-MB-231	IC₅₀	18.9 μM Compound: Tamoxifen	Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay Antiproliferative activity against estrogen receptor-deficient human MDA-MB-231 cells expressing estrogen receptor after 48 hrs by MTT assay	[PMID: 21871812]
MDA-MB-231	IC₅₀	19 μM Compound: Tamoxifen	Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay	[PMID: 12565971]
MDA-MB-231	IC₅₀	20 μM Compound: tamoxifene	Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human estrogen receptor deficient MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 19423356]
MDA-MB-231	IC₅₀	24 μM Compound: tamoxifen	Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay Anticancer activity against estrogen-positive human MDA-MB-231 cells after 18 hrs by MTT assay	[PMID: 19446930]
MDA-MB-231	IC₅₀	25.1 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
MDA-MB-231	IC₅₀	27 μM Compound: Tam	Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human ER negative MDA-MB-231 cells after 48 hrs by MTT assay	10.1039/C4MD00289J
MDA-MB-231	IC₅₀	35.8 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 33340662]
MDA-MB-231	IC₅₀	38.97 μM Compound: Tam	Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay	[PMID: 25222876]
MDA-MB-231	IC₅₀	47.1 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 30360952]
MDA-MB-231	IC₅₀	5.9 μM Compound: Tamoxifen	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in colony formation incubated for 7 days by crystal violet staining based assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	64.85 μM Compound: 1, TAM	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 23860592]
MDA-MB-231	IC₅₀	69.7 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs	[PMID: 33139111]
MDA-MB-231	IC₅₀	7 μM Compound: Tamoxifen	Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against ER-negative human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 33373820]
MDA-MB-231	IC₅₀	7.85 μg/mL Compound: Tamoxifen	Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay Inhibition of estradiol-induced proliferation in human MDA-MB-231 cells after 72 hrs by Cell-titer-Glo assay	[PMID: 28442256]
MDA-MB-231	IC₅₀	75 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	[PMID: 33234343]
MDA-MB-231	IC₅₀	75 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 96 hrs by MTT assay	[PMID: 25164760]
MDA-MB-231	IC₅₀	84.6 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 25164760]
MDA-MB-231	IC₅₀	9.86 μM Compound: TAM	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 19740667]
MDA-MB-231	IC₅₀	9.96 μM Compound: Tamoxifen	Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 29054359]
MDA-MB-435	GI₅₀	3.16 μM Compound: TAM	Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-435 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MDA-MB-435S	IC₅₀	5.5 μM Compound: Tamoxifen	Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay Cytotoxicity against human MDA-MB-435S cells assessed as cell viability by MTT assay	[PMID: 26079090]
MDA-MB-468	IC₅₀	14.99 μM Compound: Tam	Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay Cytotoxicity against human ER negative MDA-MB-468 cells after 48 hrs by MTT assay	10.1039/C4MD00289J
MDA-MB-468	GI₅₀	2.5 μM Compound: TAM	Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MDA-MB-468 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MEL-JUSO	EC₅₀	14.6 μM Compound: TAM	Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay Antiproliferative activity against human MelJuSo cells assessed as reduction in cell viability measured after 24 hrs by celltiter-blue assay	[PMID: 31099568]
M-HeLa	IC₅₀	28 μM Compound: Tamoxifen	Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay Antiproliferative activity against human M-HeLa cells assessed as reduction in cell viability after 24 hrs by DAPI/propidium iodide staining based assay	[PMID: 31673312]
M-HeLa	IC₅₀	28 μM Compound: Tamoxifen	Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method Antiproliferative activity against human M-HeLa cells by fluorescence based viable cell counting method	[PMID: 31610378]
MIA PaCa-2	IC₅₀	33.12 μM Compound: Tam	Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay	[PMID: 25222876]
MOLT-4	GI₅₀	2.5 μM Compound: TAM	Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human MOLT4 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
MRC5	CC₅₀	10 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay Cytotoxicity against human MRC5 cells measured after 7 days by MTT assay	[PMID: 33667089]
MRC5	IC₅₀	10.9 μM Compound: TAM	Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis Cytotoxicity against human MRC5 cells assessed as cell viability after 4 to 7 days by Alamar Blue staining based fluorometric analysis	[PMID: 26922226]
MRC5	IC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay	[PMID: 30879839]
MRC5	CC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 24 hrs by resazurin dye based fluorimetric assay	[PMID: 30857749]
MRC5	IC₅₀	11.09 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay Cytotoxicity against human MRC5 cells after 24 hrs by resazurin dye based assay	[PMID: 30692024]
MRC5	IC₅₀	17.2 μM Compound: Tamoxifen	Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis Cytotoxicity against human MRC5 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis	[PMID: 36242986]
MSTO-211H	GI₅₀	23.3 μM Compound: 1	Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay Antiproliferative activity against human MSTO-211H cells after 72 hrs by trypan blue assay	[PMID: 23735829]
NCI/ADR-RES	IC₅₀	11.13 μM Compound: Tamoxifen	Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay Cytotoxicity against human MCF7/ADR cells after 48 hrs by MTT assay	[PMID: 23022281]
NCI-H460	GI₅₀	4.48 μM Compound: Tamoxifen	Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay Anticancer activity against human NCI-H460 cells after 24 hrs by SRB assay	[PMID: 19733085]
NIH3T3	IC₅₀	> 100 μM Compound: Tam	Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay	[PMID: 25222876]
NIH3T3	IC₅₀	11.4 μM Compound: TAM	Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay Antiproliferative activity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 23287057]
NIH3T3	IC₅₀	7.26 μM Compound: 2	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 22749392]
OVCAR-5	GI₅₀	32 μM Compound: 1	Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay Cytotoxicity against human OVCAR5 cells assessed as cell growth inhibition after 72 hrs by MTS assay	[PMID: 27128175]
PC-3	IC₅₀	> 1000 nM Compound: 7	Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay	[PMID: 33479633]
PC-3	IC₅₀	10 μM Compound: TAM	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 23287057]
PC-3	IC₅₀	15.8 μM Compound: TAM	Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human PC-3 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 34153643]
PC-3	IC₅₀	7 μM Compound: Tamoxifen	Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay Antiproliferative activity against human PC3 cells after 24 hrs by MTT assay	[PMID: 24880230]
RAW264.7	CC₅₀	11.1 μM Compound: Tamoxifen	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability after 24 hrs by neutral red dye based assay	[PMID: 31703818]
RAW264.7	IC₅₀	18.5 μM Compound: Tamoxifen	Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth measured after 72 hrs by resazurin staining based microscopic analysis	[PMID: 36242986]
SH-SY5Y	IC₅₀	20 μM Compound: Tamoxifen	Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis Inhibition of PKC in human SH-SY5Y cells assessed as inhibition of PMA-stimulated MARCKS phosphorylation preincubated for 1 hr followed by PMA-stimulation for 15 mins by Western blot analysis	[PMID: 27647375]
SK-BR-3	IC₅₀	< 1000 μM Compound: Tamoxifen	Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 72 hrs by Hoechst 33342/propidium iodide staining based fluorescence analysis	[PMID: 36603398]
SK-BR-3	GI₅₀	12.5 μM Compound: Tamoxifen	Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human SKBR3 cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
SK-BR-3	IC₅₀	28.32 μM Compound: Tamoxifen	Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay	[PMID: 33340662]
SK-BR-3	ED₅₀	5 μg/mL Compound: TAM	Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay Cytotoxicity against estrogen receptor deficient human SKBR3 cells overexpressing human epidermal growth factor receptor 2 after 72 hrs by SRB assay	[PMID: 19425534]
SK-MEL-28	IC₅₀	1.86 μg/mL Compound: Tomoxifen	Cytotoxicity against human SK-MEL-28 cells by alamar blue assay Cytotoxicity against human SK-MEL-28 cells by alamar blue assay	[PMID: 11720540]
SK-OV-3	GI₅₀	10 μM Compound: TAM	Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
SK-OV-3	GI₅₀	6.4 μM Compound: Tamoxifen	Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay Anticancer activity against human SKOV3 cells after 24 hrs by SRB assay	[PMID: 19733085]
SNB-75	GI₅₀	5.01 μM Compound: TAM	Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human SNB75 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
T47D	IC₅₀	0.1 μM Compound: Tamoxifen	Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay Antiestrogenic activity in human T47D cells expressing estrogen receptor assessed as estrogen-dependent transcription by luciferase reporter gene assay	[PMID: 19131248]
T47D	IC₅₀	1 μM Compound: Tamoxifen	Growth inhibition of human estrogen-dependent T47D cells after 72 hrs Growth inhibition of human estrogen-dependent T47D cells after 72 hrs	[PMID: 19131248]
T47D	IC₅₀	1.13 μM Compound: Tamoxifen	Cytotoxicity against human T47D cells after 5 days Cytotoxicity against human T47D cells after 5 days	[PMID: 23864928]
T47D	GI₅₀	1.99 μM Compound: TAM	Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human T47D cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
T47D	GI₅₀	10.6 μM Compound: Tamoxifen	Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay Cytotoxicity against human T47D cells assessed as growth inhibition after 120 hrs by MTT assay	[PMID: 28152429]
T47D	IC₅₀	12.1 μM Compound: Tamoxifen	Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay Cytotoxicity against Homo sapiens (human) T47D cells assessed as inhibition of cell proliferation after 72 hr by MTT assay	10.1007/s00044-012-0391-5
T47D	IC₅₀	13 μM Compound: TAM	Antiproliferative activity against human T47D cells after 48 hrs by MTT assay Antiproliferative activity against human T47D cells after 48 hrs by MTT assay	[PMID: 23287057]
T47D	IC₅₀	14.2 μM Compound: Tamoxifen	Antiproliferative activity against human T47D cells by MTT reduction assay Antiproliferative activity against human T47D cells by MTT reduction assay	[PMID: 33421712]
T47D	IC₅₀	29.9 μM Compound: Tam	Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay Cytotoxicity against human T47D cells expressing ER after 48 hrs by MTT assay	10.1039/C4MD00289J
T47D	IC₅₀	34.42 μM Compound: Tamoxifen	Antiproliferative activity against human T47D cells after 24 hrs by MTT assay Antiproliferative activity against human T47D cells after 24 hrs by MTT assay	[PMID: 30731397]
THP-1	IC₅₀	11.91 μM Compound: Tamoxifen	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	[PMID: 31884407]
UO-31	GI₅₀	6.3 μM Compound: TAM	Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human UO31 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 26896706]
Vero	IC₅₀	15.9 μM Compound: Tamoxifen	Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against african green monkey Vero cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23786452]
Vero	IC₅₀	36.2 μM Compound: Tamoxifen	Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against african green monkey Vero cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
Vero	IC₅₀	5.7 μM Compound: Tamoxifen	Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as cell viability by MTT assay	[PMID: 26079090]

體外研究
(In Vitro)

Tamoxifen (ICI 47699) 對 MCF-7 細(xì)胞 (EC₅₀=1.41 μM) 表現(xiàn)出強(qiáng)烈的抑制作用，對 T47D 細(xì)胞 (EC₅₀=2.5 μM) 的抑制作用較小，但不影響 MDA-MB-231 細(xì)胞^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Tamoxifen可誘導(dǎo)腎病綜合癥模型和肝損傷模型。Tamoxifen 在雄性 Sprague-Dawley 大鼠中 (體重295-340g)，靜脈注射 Tamoxifen (10 mg/kg) 后的藥代動力學(xué)數(shù)據(jù)顯示：最大血漿濃度達(dá) 1566 ng/mL，0 至 24 小時的血漿濃度-時間曲線下面積為 4757 ng·h/mL，而 0 至 1 小時的相應(yīng)面積為 5006 ng·h/mL，藥物的半衰期為 5.8 小時^[8]^[10]。

誘導(dǎo)肝損傷模型^[8]^[9]

致病原理

Tamoxifen 會降低己糖單磷酸旁路，從而增加大鼠肝細(xì)胞中氧化應(yīng)激的發(fā)生率，導(dǎo)致肝臟損傷。

具體造模方法：

大鼠：白化病大鼠 • 雌性 • 處理 7 天
給藥方式：45 mg/kg • 腹腔注射 • 每天一次，連續(xù) 7 天

Note

(1) 大鼠處于標(biāo)準(zhǔn)的實(shí)驗(yàn)室環(huán)境下，即 12 小時光照/12 小時黑暗循環(huán)，溫度保持在 25 ± 2°C，且可以自由獲取食物和水。
(2) 實(shí)驗(yàn)結(jié)束后，動物在輕度乙醚麻醉下通過頸椎脫位處死。將血液樣本收集在肝素化的離心管中，離心得到血清。剖開腹部，立即解剖取出肝臟，用冰冷的等滲鹽水洗滌，并在兩張濾紙之間吸干。肝臟用鋁箔包裹，在-80℃下保存。使用超聲儀在冰冷的0.1 M 磷酸鉀緩沖液（PH 7.5）中制備10%（w/v）的肝勻漿。

造模成功指標(biāo)

分子變化：抗氧化酶(谷胱甘肽S轉(zhuǎn)移酶、谷胱甘肽過氧化物酶和過氧化氫酶) 活性顯著 ↓，還原型谷胱甘肽含量 ↓，同時硫代巴比妥酸反應(yīng)物質(zhì)(TBARS) 和肝臟轉(zhuǎn)氨酶(血清谷丙轉(zhuǎn)氨酶sGPT 和血清谷草轉(zhuǎn)氨酶sGOT) 水平顯著 ↑。

相關(guān)產(chǎn)品： /

拮抗產(chǎn)品： /

誘導(dǎo) Cre 重組^[8]^[3]

致病原理

MerCreMer 小鼠是一種表達(dá)Cre 重組酶蛋白，且該蛋白與兩個突變型雌激素受體配體結(jié)合域(Mer) 融合的小鼠。在沒有Tamoxifen 的誘導(dǎo)下，Cre 重組酶處于無活性狀態(tài)，當(dāng) Tamoxifen 誘導(dǎo)后，Tamoxifen 的代謝產(chǎn)物 4-OHT (雌激素類似物) 與Mer 結(jié)合，發(fā)揮 Cre 重組酶活性，進(jìn)而實(shí)現(xiàn)基因敲除。

具體造模方法：

小鼠：轉(zhuǎn)基因小鼠 • 成年 (6 周齡)
給藥方式：75 mg/kg • 腹腔注射 • 每天一次，連續(xù) 5 天

Note

取經(jīng) Tamoxifen 或生理鹽水鹽處理的對照小鼠心臟，用磷酸鹽緩沖鹽水逆行灌注主動脈、左心室和冠狀血管 2 分鐘，然后在室溫下用 X-gal 染色溶液灌注過夜，以檢測整個心臟 lacZ 的活性。

造模成功指標(biāo)

組織學(xué)改變：左右心室和心房中都表現(xiàn)出了 lacZ 染色，盡管由于心房壁較薄，心房染色看起來不太明顯。
心肌細(xì)胞均表現(xiàn)出 lacZ 活性。
心臟中的重組率升高，重組率為 70%。

相關(guān)產(chǎn)品： 4-Hydroxytamoxifen (HY-16950)

拮抗產(chǎn)品： /

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Aldh1l1-cre/ERT2 x Ai95 mice^[3]
Dosage:	75 mg/kg
Administration:	Injected for 5 days at 6 weeks of age
Result:	Resulted in the excision of the floxed exon and a gene knockout.

Clinical Trial

分子量

371.51

Formula

C₂₆H₂₉NO

CAS 號

10540-29-1

性狀

固體

顏色

White to off-white

中文名稱

他莫昔芬；三苯氧胺；它莫西芬

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

Ethanol 中的溶解度 : 50 mg/mL (134.59 mM; 超聲助溶)

DMSO 中的溶解度 : 25 mg/mL (67.29 mM; 超聲助溶 (<60°C); 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響，請使用新開封的 DMSO)

配制儲備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	2.6917 mL	13.4586 mL	26.9172 mL
5 mM	0.5383 mL	2.6917 mL	5.3834 mL
10 mM	0.2692 mL	1.3459 mL	2.6917 mL

查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C儲存時，請?jiān)?個月內(nèi)使用，-20°C儲存時，請?jiān)?個月內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動物實(shí)驗(yàn)：

請根據(jù)您的實(shí)驗(yàn)動物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.60 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (5.60 mM); 懸濁液; 超聲助溶

此方案可獲得 2.08 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請依序添加每種溶劑： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.60 mM); 澄清溶液

此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個月以上的動物實(shí)驗(yàn)酌情使用。
以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中，混合均勻。

以下溶解方案，請直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶。

方案一

請依序添加每種溶劑： Corn Oil
Solubility: 40 mg/mL (107.67 mM); 澄清溶液; 超聲助溶

動物溶解方案計(jì)算器

請輸入動物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動物的平均體重

每只動物的給藥體積

μL

動物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動物的量

請輸入您的動物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購。，Tween 80，均可在 MCE 網(wǎng)站選購。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

您所需的儲備液濃度超過該產(chǎn)品的實(shí)測溶解度，以下方案僅供參考，如有需要，請與 MCE 中國技術(shù)支持聯(lián)系。

動物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請謹(jǐn)慎選擇該方案。

請確保第一步儲備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.92%

選擇批次：

Data Sheet (695 KB) SDS (701 KB)

COA (286 KB) LCMS (112 KB) 元素分析報(bào)告 (209 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]

[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]

[3]. Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177(5):1280-1292.e20. [Content Brief]

[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]

[5]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. [Content Brief]

[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]

[7]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]

[8]. Sohal DS, et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res. 2001 Jul 6;89(1):20-5. [Content Brief]

Tamoxifen 相關(guān)分類

完整儲備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

DMSO / Ethanol	1 mM	2.6917 mL	13.4586 mL	26.9172 mL	67.2929 mL
	5 mM	0.5383 mL	2.6917 mL	5.3834 mL	13.4586 mL
	10 mM	0.2692 mL	1.3459 mL	2.6917 mL	6.7293 mL
	15 mM	0.1794 mL	0.8972 mL	1.7945 mL	4.4862 mL
	20 mM	0.1346 mL	0.6729 mL	1.3459 mL	3.3646 mL
	25 mM	0.1077 mL	0.5383 mL	1.0767 mL	2.6917 mL
	30 mM	0.0897 mL	0.4486 mL	0.8972 mL	2.2431 mL
	40 mM	0.0673 mL	0.3365 mL	0.6729 mL	1.6823 mL
	50 mM	0.0538 mL	0.2692 mL	0.5383 mL	1.3459 mL
	60 mM	0.0449 mL	0.2243 mL	0.4486 mL	1.1215 mL
Ethanol	80 mM	0.0336 mL	0.1682 mL	0.3365 mL	0.8412 mL
Ethanol	100 mM	0.0269 mL	0.1346 mL	0.2692 mL	0.6729 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2024 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tamoxifen (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Customer Review

Other Forms of Tamoxifen:

MCE 顧客使用本產(chǎn)品發(fā)表的 114 篇科研文獻(xiàn)

Tamoxifen 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

查看 HSP 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Tamoxifen 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Tamoxifen (Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen)

Customer Review

Other Forms of Tamoxifen:

Tamoxifen 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 114 篇科研文獻(xiàn)

Tamoxifen 相關(guān)產(chǎn)品

•相關(guān)化合物庫:

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 Estrogen Receptor/ERR 亞型特異性產(chǎn)品:

查看 HSP 亞型特異性產(chǎn)品:

生物活性

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Tamoxifen 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Tamoxifen 相關(guān)分類

完整儲備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z